Asaf Maoz, MD, on Pancreatic Surveillance Eligibility Criteria
2025 ASCO Annual Meeting
Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, discusses the sensitivity of age and family history criteria for determining eligibility for pancreatic cancer surveillance among individuals with a hereditary risk for the malignancy (Abstract 10500).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Our study looked at pancreatic cancer surveillance eligibility criteria among individuals who have a genetic risk of pancreatic cancer. Individuals who carry a pathogenic germline variant in a pancreatic cancer predisposition gene have an elevated risk of pancreatic cancer over the lifetime, and when surveillance has been done for these individuals, we have seen that this results in an earlier stage at diagnosis and improved survival compared with historical cohorts. However, not everyone who carries a pathogenic germline variant that predisposes them to pancreatic cancer has been eligible for pancreatic cancer surveillance and eligibility criteria have restricted eligibility based on age and a family history of pancreatic cancer. Our study was meant to look at the proportion of pathogenic germline variant carriers who would have been eligible for pancreatic cancer surveillance at the time of their pancreatic cancer diagnosis, and we leveraged a laboratory cohort to look at this question. We had over 11,000 individuals in the cohort and over 900 individuals who had a pathogenic germline variant that predisposes them to pancreatic cancer. Our results show that the age criteria for pancreatic cancer surveillance eligibility did very well, with over 85% of individuals who had a pathogenic germline variant and developed pancreatic cancer meeting the age eligibility criteria for surveillance. However, the family history criteria did poorly with only 22% of individuals who carry pathogenic germline variants and developing pancreatic cancer meeting the family history criteria when it's applicable. Our results suggest that having a family history of pancreatic cancer needs to be reevaluated as an eligibility criteria for pancreatic cancer surveillance among those who have a genetic risk of pancreatic cancer. We feel that our results support the recent removal of the family history requirement for pancreatic cancer surveillance eligibility for those who have germline pathogenic variants in BRCA2 and ATM.
The ASCO Post Staff
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, reviews the final analysis of phase II CAPTIVATE study demonstrating the long-term efficacy and safety of ibrutinib plus venetoclax for previously untreated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including in patients with high-risk genomic features. The 5.5-year progression-free survival and overall survival rates were 66% and 97%, respectively (Abstract 7036).
The ASCO Post Staff
Angela R. Bradbury, MD, of the University of Pennsylvania, presents findings from the eREACH trial—a randomized study of an eHEALTH delivery alternative for cancer genetic testing for hereditary predisposition in patients with metastatic cancers (Abstract 10502).
The ASCO Post Staff
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents findings from the phase III, double-blind ctDNA-guided SERENA-6 trial, which evaluated the combination of camizestrant plus a CDK4/6 inhibitor to treat emergent ESR1 mutations during first-line endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer (LBA4).
The ASCO Post Staff
Andrew J. Armstrong, MD, MS, of Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, discusses the 5-year overall survival analysis of the ARCHES trial, which investigated enzalutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer (Abstract 5005).
The ASCO Post Staff
Christopher M. Booth, MD, of Queen’s University, reviews findings from the randomized phase III Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE) trial, which evaluated the impact of a structured exercise program on disease-free survival in patients with stage III or high-risk stage II colon cancer (Abstract LBA3510).